Media coverage about Intra-Cellular Therapies (NASDAQ:ITCI) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive media coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Intra-Cellular Therapies earned a daily sentiment score of 0.22 on Accern’s scale. Accern also assigned news articles about the biopharmaceutical company an impact score of 45.3522636313214 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
These are some of the media stories that may have effected Accern’s scoring:
- Intra-Cellular Therapies (ITCI) Lowered to “Hold” at Zacks Investment Research (americanbankingnews.com)
- Intra-Cellular Therapies, Inc. (ITCI) stock ends Yesterday with change of 0.16% – Nasdaq Fortune (press release) (nasdaqfortune.com)
- Intra-Cellular Therapies (ITCI) Raised to Buy at Zacks Investment Research (americanbankingnews.com)
- Chairman, President & CEO of Intra-Cellular Therapies, Inc. (NASDAQ:ITCI), Mates Sharon, sells 6,604 shares worth $115,438 (empowerednews.net)
- Intra-Cellular Therapies Inc. (ITCI) Chairman Sharon Mates Sells 6,604 Shares (americanbankingnews.com)
Intra-Cellular Therapies (ITCI) opened at $18.06 on Wednesday. The company has a market capitalization of $985.67, a PE ratio of -8.25 and a beta of 0.72. Intra-Cellular Therapies has a 52 week low of $7.85 and a 52 week high of $22.67.
A number of brokerages have recently issued reports on ITCI. Zacks Investment Research raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating and set a $21.00 target price for the company in a research report on Saturday. BidaskClub raised shares of Intra-Cellular Therapies from a “strong sell” rating to a “sell” rating in a research report on Friday, January 5th. ValuEngine cut shares of Intra-Cellular Therapies from a “sell” rating to a “strong sell” rating in a research report on Wednesday, September 27th. Canaccord Genuity began coverage on shares of Intra-Cellular Therapies in a research report on Friday, December 15th. They issued a “buy” rating and a $31.00 target price for the company. Finally, SunTrust Banks raised shares of Intra-Cellular Therapies from a “hold” rating to a “buy” rating in a research report on Wednesday, November 8th. Two equities research analysts have rated the stock with a sell rating, one has assigned a hold rating and nine have issued a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $26.11.
In related news, Chairman Sharon Mates sold 6,604 shares of the business’s stock in a transaction dated Monday, January 8th. The stock was sold at an average price of $17.48, for a total value of $115,437.92. Following the completion of the transaction, the chairman now owns 1,088,707 shares of the company’s stock, valued at $19,030,598.36. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CFO Lawrence J. Hineline sold 3,192 shares of the business’s stock in a transaction dated Thursday, January 4th. The shares were sold at an average price of $15.67, for a total value of $50,018.64. Following the completion of the transaction, the chief financial officer now directly owns 68,686 shares of the company’s stock, valued at approximately $1,076,309.62. The disclosure for this sale can be found here. In the last ninety days, insiders sold 49,410 shares of company stock valued at $802,481. 21.00% of the stock is owned by insiders.
ILLEGAL ACTIVITY WARNING: “Intra-Cellular Therapies (ITCI) Getting Somewhat Favorable News Coverage, Analysis Shows” was first published by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://sportsperspectives.com/2018/01/17/intra-cellular-therapies-itci-getting-somewhat-favorable-news-coverage-analysis-shows.html.
About Intra-Cellular Therapies
Intra-Cellular Therapies, Inc (ITI) is a biopharmaceutical company. The Company is focused on the discovery and clinical development of small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS).
Receive News & Ratings for Intra-Cellular Therapies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intra-Cellular Therapies and related companies with MarketBeat.com's FREE daily email newsletter.